347 results
8-K
EX-99.2
EYPT
EyePoint Pharmaceuticals Inc
6 May 24
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
9:25am
Primary outcome: Percentage of patients with a ≥2 step DRSS improvement score at week 36 (9 months) as evaluated by an independent reading center Key
8-K
EX-1.1
153u2y
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
424B5
heqk3bge79pzdtjc1
7 Dec 23
Prospectus supplement for primary offering
6:11am
424B5
la3hbbbon9 lz15
4 Dec 23
Prospectus supplement for primary offering
5:31pm
S-8
EX-23.1
qklf9oqr
20 Oct 23
Registration of securities for employees
5:15pm
S-8
gg6bun xv
20 Oct 23
Registration of securities for employees
5:15pm
8-K
mddcph9m1mycxz
10 Jul 23
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
7:05am
8-K
EX-99.1
y5hlhp frx3
10 Jul 23
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
7:05am
8-K
cu0d97q2jn7p8
21 Jun 23
Departure of Directors or Certain Officers
7:53am
8-K
EX-2.1
wbo ebq7gn
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am
8-K
EX-10.1
ppmxbb
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am